JP2023517243A5 - - Google Patents
Info
- Publication number
- JP2023517243A5 JP2023517243A5 JP2022554833A JP2022554833A JP2023517243A5 JP 2023517243 A5 JP2023517243 A5 JP 2023517243A5 JP 2022554833 A JP2022554833 A JP 2022554833A JP 2022554833 A JP2022554833 A JP 2022554833A JP 2023517243 A5 JP2023517243 A5 JP 2023517243A5
- Authority
- JP
- Japan
- Prior art keywords
- bcma
- subject
- nilogacestat
- dihydrobromide
- cell maturation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025139609A JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 | |
| US62/989,372 | 2020-03-13 | ||
| PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139609A Division JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517243A JP2023517243A (ja) | 2023-04-24 |
| JP2023517243A5 true JP2023517243A5 (OSRAM) | 2024-03-21 |
| JP7781764B2 JP7781764B2 (ja) | 2025-12-08 |
Family
ID=75396879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554833A Active JP7781764B2 (ja) | 2020-03-13 | 2021-03-12 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
| JP2025139609A Pending JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139609A Pending JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (OSRAM) |
| EP (1) | EP4132515A1 (OSRAM) |
| JP (2) | JP7781764B2 (OSRAM) |
| KR (1) | KR20230009873A (OSRAM) |
| CN (1) | CN115916188A (OSRAM) |
| AR (1) | AR121566A1 (OSRAM) |
| AU (1) | AU2021236340A1 (OSRAM) |
| BR (1) | BR112022018251A2 (OSRAM) |
| CA (1) | CA3171267A1 (OSRAM) |
| CL (1) | CL2022002479A1 (OSRAM) |
| CO (1) | CO2022014388A2 (OSRAM) |
| IL (1) | IL296075A (OSRAM) |
| MX (1) | MX2022011258A (OSRAM) |
| PE (1) | PE20230614A1 (OSRAM) |
| TW (1) | TW202200132A (OSRAM) |
| WO (1) | WO2021183934A1 (OSRAM) |
| ZA (1) | ZA202209989B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI905452B (zh) | 2021-09-01 | 2025-11-21 | 美商斯普林渥克斯治療有限公司 | 尼羅司他（ｎｉｒｏｇａｃｅｓｔａｔ）之合成 |
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
| CA3239013A1 (en) * | 2021-11-23 | 2023-06-01 | Anantha Rajmohan MUTHUSAMY | Solid state forms of nirogacestat salts |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| CN119486713A (zh) | 2022-05-20 | 2025-02-18 | 斯普林渥克斯治疗有限公司 | 尼罗加司他治疗 |
| EP4678635A1 (en) * | 2023-03-09 | 2026-01-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of nirogacestat dihydrobromate, and preparation method therefor and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120065A1 (en) * | 2014-02-05 | 2015-08-13 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides |
| EP3662909A1 (en) * | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| JP2020507605A (ja) * | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| US20200055948A1 (en) * | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN110622566B (zh) | 2017-05-05 | 2021-04-20 | 华为技术有限公司 | 一种辅助数据传输方法、设备及系统 |
| EP3706754A1 (en) * | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
| US20210069194A1 (en) * | 2018-01-17 | 2021-03-11 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| CA3101340A1 (en) * | 2018-05-24 | 2019-11-28 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| AU2019277029C1 (en) * | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| KR102923588B1 (ko) * | 2019-04-10 | 2026-02-05 | 스프링웍스 테라퓨틱스, 인크. | 항 bcma 항체 및 감마 세크레타제 억제제의 조합 요법 |
| EP4010322B1 (en) * | 2019-08-09 | 2025-11-05 | Pfizer Inc. | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
-
2021
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
- 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
-
2022
- 2022-09-07 ZA ZA2022/09989A patent/ZA202209989B/en unknown
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
-
2025
- 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Czuczman et al. | Rituximab in combination with CHOP or fludarabine in low-grade lymphoma | |
| Boye et al. | An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab | |
| DK2055313T3 (en) | Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody | |
| US9458241B2 (en) | Antibody induced cell membrane wounding | |
| US11220548B2 (en) | Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody | |
| US20050112130A1 (en) | Enhanced B cell cytotoxicity of CDIM binding antibody | |
| Sacchi et al. | Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab | |
| EA004107B1 (ru) | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2008530142A5 (OSRAM) | ||
| US20180228893A1 (en) | Combinations and uses thereof | |
| Lugtenburg et al. | First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBodyŪ-CD3ŨCD20) in B-Cell Non-Hodgkin Lymphomas | |
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| Anastasia et al. | Novel drugs in follicular lymphoma | |
| JP2022532519A5 (OSRAM) | ||
| Arcaini et al. | Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma | |
| Jäeger et al. | Rituximab (anti‐CD20 monoclonal antibody) as consolidation of first‐line CHOP chemotherapy in patients with follicular lymphoma: a phase II study | |
| Kawano et al. | The impact of a humanized CCR4 antibody (Mogamulizumab) on patients with aggressive-type adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation | |
| Candelaria | Advances in the diagnosis and control of lymphomas | |
| Longo | Biologic agents and approaches in the management of patients with lymphoma: a critical appraisal | |
| AU2020339737B2 (en) | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells | |
| JP2019524780A (ja) | プロテアソーム阻害剤及び抗ｃｄ３０抗体の組み合わせ | |
| Hagemeister | Mantle cell lymphoma: non-myeloablative versus dose-intensive therapy | |
| Qu et al. | ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R‐CHOP‐LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON‐GCB DLBCL. | |
| WO2025021587A1 (en) | Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof |